Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Study of Ninerafaxstat (IMB-1018972) in Angina due to Chronic Coronary Syndrome
2020-004455-32Phase 2Completed
- Sponsor
- Imbria Pharmaceuticals
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Coronary Syndrome (CCS), coronary arteriosclerosis and angina pectoris comparing Ninerafaxstat with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Dec 2020; status: completed.
02
Drugs
ninerafaxstat
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on 2020-004455-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004455-32.